Patents by Inventor Kevin X. Chen

Kevin X. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR
    Publication number: 20200239465
    Abstract: Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.
    Type: Application
    Filed: September 27, 2018
    Publication date: July 30, 2020
    Inventors: Kevin X CHEN, Kai ZHOU, Boyu HU, Minliang XIAO, Shuhui CHEN
  • BICYLIC COMPOUND ACTING AS AN INHIBITOR
    Publication number: 20200231597
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X CHEN, Kai ZHOU, Yanxin YU, Boyu HU, Linghui WU, Xiaoyuan CHEN, Jiangfeng LIN, Haomin CHEN, Xiangjian WANG, Xiquan ZHANG, Xin TIAN, Hongjiang XU
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20200188397
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 28, 2019
    Publication date: June 18, 2020
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR
    Publication number: 20200131184
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Application
    Filed: April 6, 2018
    Publication date: April 30, 2020
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: KEVIN X CHEN, Yanxin YU, Xinde CHEN, Li ZHANG, Zhaoguo CHEN, Cheng XIE, Xiaofei WANG, Linghui WU, Guoping HU, Jian LI, Shuhui CHEN
  • AZETIDINE DERIVATIVE
    Publication number: 20200115392
    Abstract: Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma.
    Type: Application
    Filed: February 28, 2018
    Publication date: April 16, 2020
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jian XIONG, Cheng XIE, Kevin X CHEN, Xiongbin XU, Xuejin ZHANG, Zhen GONG, Jian LI, Shuhui CHEN, Aiming ZHANG, Zhulian JIANG, Xiquan ZHANG, Xin TIAN
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20190241558
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 21, 2018
    Publication date: August 8, 2019
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • ANTI-HCMV VIRUS COMPOUND
    Publication number: 20190202838
    Abstract: Disclosed are a class of fused cyclic compounds against the HCMV virus, and use thereof in the preparation of a drugs for treating diseases associated with the HCMV virus. In particular, disclosed is the compound shown in formula (II) and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 8, 2017
    Publication date: July 4, 2019
    Inventors: Jian XIONG, Jingjing WANG, Wentao WU, Haizhong TAN, Xuanjia PENG, Yang ZHANG, Kevin X. CHEN, Jian LI, Shuhui CHEN
  • Biheteroaryl compounds and uses thereof
    Patent number: 10010549
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180133219
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170333406
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 23, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 9796705
    Abstract: The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: October 24, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin X. Chen, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
  • Therapeutic compounds and uses thereof
    Patent number: 9763922
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 19, 2017
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20170008879
    Abstract: The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.
    Type: Application
    Filed: September 26, 2016
    Publication date: January 12, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin X. Chen, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
  • 5?-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
    Patent number: 9408863
    Abstract: The present invention relates to 5?-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3? are as defined herein. The present invention also relates to compositions comprising at least one 5?-Substituted Nucleoside Analog, and methods of using the 5?-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: August 9, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Vishal A. Verma, Ashok Arasappan, F. George Njoroge, Kevin X. Chen
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20160158207
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160052940
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: ANTHONY ESTRADA, LITING DONG, KEVIN X. CHEN, PAUL GIBBONS, MALCOLM HUESTIS, TERRY KELLAR, WEN LIU, CHANGYOU MA, JOSEPH LYSSIKATOS, ALAN OLIVERO, SNAHEL PATEL, DANIEL SHORE, MICHAEL SIU
  • Fused tricyclic aryl compounds useful for the treatment of viral diseases
    Patent number: 9139569
    Abstract: The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: September 22, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Stuart B. Rosenblum, Kevin X. Chen, Joseph A. Kozlowski, F. George Njoroge, Craig A. Coburn
  • Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
    Patent number: 8980920
    Abstract: The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: March 17, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Qingbei Zeng, Kevin X. Chen, Anilkumar Gopinadhan Nair, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
  • Tricyclic indole derivatives and methods of use thereof
    Patent number: 8901139
    Abstract: The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Srikanth Venkatraman, Anilkumar Gopinadhan Nair, Kevin X. Chen, Francisco Velazquez, Qingbei Zeng, Duan Liu, Yueheng Jiang, Joseph A. Kozlowski, F. George Njoroge, Stuart B. Rosenblum, Stephen J. Gavalas, Patrick A. Pinto, Oleg B. Selyutin, Bancha Vibulbhan
  • 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20140221304
    Abstract: The present invention relates to 5?-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3? are as defined herein. The present invention also relates to compositions comprising at least one 5?-Substituted Nucleoside Analog, and methods of using the 5?-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: July 10, 2012
    Publication date: August 7, 2014
    Inventors: Vishal A. Verma, Ashok Arasappan, F. George Njoroge, Kevin X. Chen